leadf
logo-loader
viewSynairgen PLC

Synairgen plans after £80m share sale to fund crucial trial of breakthrough COVID-19 drug

Synairgen PLC's Richard Marsden (LON:SNG) talks to Proactive London's Katie Pilbeam about the £80m share placing to finance its lead drug through final-stage clinical trials in patients with severe coronavirus (COVID-19).

Marsden explains the reason behind involving 900 patients in 20 countries for the phase III clinical trial which is set to get away in November. He says he wants to 'complete the trial as quickly as possible' and the 'eventual data set will have lots of different ethnicities and a different standard of care in the background'.

Synairgen has teamed up with Parexel to enable such a large amount of research to be conducted and 'enable rapid approvals around the world'.

Marsden says if all goes to plan 'we would have finished a phase II and III programme all in one year', which is 'very unusual'.

Quick facts: Synairgen PLC

Price: 165 GBX

AIM:SNG
Market: AIM
Market Cap: £329.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read